This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Early Winners & Losers

Threshold Pharmaceuticals (THLD - Get Report) jumped more than 15% in extended trading Wednesday after the Redwood City, Calif., company announced positive results for midphase testing of its advanced pancreatic cancer treatment. The company said its combination of glufosfamide and gemcitabine induced partial response -- defined here as a 30% combined shrinkage of the largest-diameter target lesions -- in 21% of patients tested. Stable disease was seen in 36% of the test subjects. The drug combination also was "generally well tolerated," Threshold said, "with no new unexpected adverse events."

In one possible piece of bad news, Threshold added that the drugs may jointly induce slightly more treatment-related nephrotoxicity, or toxicity to kidney cells, than either drug would do alone. But shares were trading up 50 cents, or 15.6%, to $3.70.

On2 Technologies (ONT) gained after an analyst with ThinkEquity Partners began coverage on the video compression technology firm with a buy rating, targeting a per-share price of $1.40. Shares of the Clifton Park, N.Y.-based company were adding 4 cents, or 3.7%, to $1.13.

Salt Lake City's Sento (SNTO) tanked after it swung to a fiscal second-quarter loss. The customer-service small-cap said it lost $2.6 million, or 65 cents a share, in the quarter ended Sept. 30, down from a $310,000 profit, or 8 cents a share, a year ago. Revenue rose 39% to $13.6 million -- which, the company pointed out, topped its own earlier target range of $12 million to $12.5 million. Shares were losing 63 cents, or 19.4%, to $2.61.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CORT $5.25 3.35%
THLD $3.80 -1.81%
WOOF $54.58 -0.64%
AAPL $118.03 -0.71%
FB $105.41 -0.31%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs